S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The Financial Day of Reckoning Has Begun (Ad)
NASDAQ:ARWR

Arrowhead Pharmaceuticals - ARWR Stock Forecast, Price & News

$45.88
-1.75 (-3.67%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$45.71
$47.13
50-Day Range
$27.79
$48.31
52-Week Range
$26.81
$84.83
Volume
457,036 shs
Average Volume
783,829 shs
Market Capitalization
$4.86 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.83

Arrowhead Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
54.4% Upside
$70.83 Price Target
Short Interest
Healthy
4.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.57
Upright™ Environmental Score
News Sentiment
0.04mentions of Arrowhead Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.08) to ($1.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

698th out of 1,122 stocks

Pharmaceutical Preparations Industry

350th out of 551 stocks

ARWR stock logo

About Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals Stock Down 3.7 %

Shares of Arrowhead Pharmaceuticals stock traded down $1.75 on Wednesday, reaching $45.88. The stock had a trading volume of 457,036 shares, compared to its average volume of 783,829. The company has a 50 day moving average price of $39.14 and a 200 day moving average price of $41.63. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.16. Arrowhead Pharmaceuticals has a 1 year low of $26.81 and a 1 year high of $84.83. The stock has a market capitalization of $4.86 billion, a P/E ratio of -31.48 and a beta of 1.37.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Rating) last released its earnings results on Thursday, August 4th. The biotechnology company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.17). The company had revenue of $32.41 million during the quarter, compared to analyst estimates of $52.61 million. Arrowhead Pharmaceuticals had a negative return on equity of 36.05% and a negative net margin of 61.58%. The firm's revenue for the quarter was down 29.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.29) earnings per share. As a group, equities research analysts forecast that Arrowhead Pharmaceuticals will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ARWR. Chardan Capital raised their target price on shares of Arrowhead Pharmaceuticals from $80.00 to $82.00 in a research report on Friday, August 5th. Robert W. Baird raised shares of Arrowhead Pharmaceuticals from a "neutral" rating to an "outperform" rating and cut their target price for the company from $71.00 to $60.00 in a research report on Wednesday, May 11th. The Goldman Sachs Group raised their target price on shares of Arrowhead Pharmaceuticals from $58.00 to $65.00 and gave the company a "buy" rating in a research report on Monday, August 8th. Piper Sandler cut their target price on shares of Arrowhead Pharmaceuticals from $89.00 to $72.00 in a research report on Wednesday, May 11th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $110.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, July 14th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $70.83.

Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Stock News Headlines

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 7%
5 Top Biotech Stocks To Watch In July 2022
See More Headlines
Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Company Calendar

Last Earnings
8/04/2022
Today
8/17/2022
Fiscal Year End
9/30/2022
Next Earnings (Estimated)
11/28/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARWR
Employees
329
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$70.83
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+54.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-140,850,000.00
Pretax Margin
-61.58%

Debt

Sales & Book Value

Annual Sales
$138.29 million
Book Value
$4.48 per share

Miscellaneous

Free Float
102,462,000
Market Cap
$4.86 billion
Optionable
Optionable
Beta
1.37

Key Executives

  • Dr. Christopher R. Anzalone Ph.D. (Age 53)
    CEO, Pres & Director
    Comp: $1.68M
  • Mr. Kenneth A. Myszkowski (Age 56)
    Chief Financial Officer
    Comp: $729.77k
  • Mr. Patrick O'Brien (Age 58)
    Chief Compliance Officer, Gen. Counsel & Corp. Sec.
    Comp: $733.13k
  • Dr. James C. Hamilton M.D. (Age 43)
    MBA, Sr. VP of Discovery & Translational Medicine
    Comp: $673.45k
  • Dr. Javier San Martin M.D. (Age 57)
    Chief Medical Officer
    Comp: $658.48k
  • Dr. Mark M. Davis Ph.D.
    Founder and Founder & Director of Insert Therapeutics Inc & Calando
  • Ms. Jane Davidson
    Head of HR & Admin., VP and Corp. Sec.
  • Dr. Vincent Anzalone CFA
    Head of Investor Relations & VP
  • Mr. Howard Lovy
    Director of Communications
  • Dr. Mark Seefeld (Age 68)
    Head of Toxicology & VP













ARWR Stock - Frequently Asked Questions

Should I buy or sell Arrowhead Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARWR shares.
View ARWR analyst ratings
or view top-rated stocks.

What is Arrowhead Pharmaceuticals' stock price forecast for 2022?

5 equities research analysts have issued 1 year price objectives for Arrowhead Pharmaceuticals' stock. Their ARWR share price forecasts range from $36.00 to $110.00. On average, they predict the company's share price to reach $70.83 in the next twelve months. This suggests a possible upside of 54.4% from the stock's current price.
View analysts price targets for ARWR
or view top-rated stocks among Wall Street analysts.

How have ARWR shares performed in 2022?

Arrowhead Pharmaceuticals' stock was trading at $66.30 at the beginning of 2022. Since then, ARWR shares have decreased by 30.8% and is now trading at $45.88.
View the best growth stocks for 2022 here
.

When is Arrowhead Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 28th 2022.
View our ARWR earnings forecast
.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced its quarterly earnings data on Thursday, August, 4th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.17. The biotechnology company earned $32.41 million during the quarter, compared to analysts' expectations of $52.61 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 36.05% and a negative net margin of 61.58%. Arrowhead Pharmaceuticals's revenue for the quarter was down 29.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.29) earnings per share.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (5.27%), JPMorgan Chase & Co. (2.83%), FMR LLC (2.59%), Northern Trust Corp (1.22%), Credit Suisse AG (1.21%) and Fiera Capital Corp (1.06%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien and William D Waddill.
View institutional ownership trends
.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $45.88.

How much money does Arrowhead Pharmaceuticals make?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a market capitalization of $4.86 billion and generates $138.29 million in revenue each year. The biotechnology company earns $-140,850,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis.

How many employees does Arrowhead Pharmaceuticals have?

The company employs 329 workers across the globe.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The official website for the company is www.arrowheadpharma.com. The biotechnology company can be reached via phone at (626) 304-3400, via email at ir@arrowheadpharma.com, or via fax at 626-304-3401.

This page (NASDAQ:ARWR) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.